))
Advancements in Heart Failure Clinical Research
Manage episode 425413603 series 2849626
İçerik BEaTS Research Radio tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan BEaTS Research Radio veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Nicole Chu from the University of Ottawa speaks with Dr. Javed Butler. Dr. Javed Butler, MD, MPH, MBA, is the President of the Baylor Scott and White Research Institute, and Senior Vice President and Maxwell A. and Gayle H. Clampitt Endowed Chair at the Baylor Scott and White Health in Dallas, Texas. He is also the Distinguished Professor of Medicine at the University of Mississippi in Jackson, Mississippi. In this episode, Dr. Butler shares with us the major findings from the recent EMPACT-MI clinical trial and his perspective on the future of heart failure therapies. The EMPACT-MI trial investigated whether a medicine called empagliflozin, a SGLT2 inhibitor, helps to lower the risk of heart failure and death in people had experienced a heart attack (myocardial infarction).
Learn more about the EMPACT-MI clinical trial https://www.nejm.org/doi/full/10.1056/NEJMoa2206286
31 bölüm
Paylaş
